Synopsis: Specialty chemical inventory with ~20 p.c development outlook pushed by ATBS growth and robust antioxidant demand, supported by diversified industrial chemical portfolio and bettering quantity momentum throughout key segments.
The article outlines an organization that targets sturdy development, which is a number one Indian producer of specialty chemical substances and natural intermediaries, commanding a major international market share in its core merchandise, ATBS and IBB.
With the market capitalization of Rs 13,715 crore, Vinati Organics Ltd’s closed at Rs 1,323, down 1.40 p.c from its earlier shut. The share of this firm gave a detrimental return of twenty-two within the final 5 years.
Administration Outlook
- ATBS Capability Growth and Demand Restoration The administration highlighted that the ATBS (Acrylamide Tertiary Butyl Sulfonic Acid) growth was accomplished in October, strengthening manufacturing capability. After some demand strain within the earlier 12 months, ATBS consumption has began bettering from April. The corporate expects quantity development of round 20 p.c going ahead, supported by higher industrial demand tendencies. ATBS is principally a performance-enhancing chemical used throughout the oil, water, and cleansing industries.
- Product Combine and Quantity Developments Within the specialty chemical substances portfolio, efficiency has been blended throughout segments. Anti-oxidants recorded robust traction with 25 p.c quantity development, whereas IB and IBB remained largely flat. General realizations have been barely decrease regardless of quantity development in choose merchandise, indicating some pricing strain available in the market.
- Development Outlook and Income Drivers The corporate expects regular development momentum forward, with ATBS volumes contributing meaningfully from the expanded capability. Income from the brand new subsidiary is anticipated to start out flowing from October. Anti-oxidants are additionally projected to ship round 15 p.c income development, supporting general topline growth.
- Margin Steerage and FY27 Expectations Administration has maintained confidence in sustaining EBITDA margins within the 26–27 p.c vary for FY27. It additionally expects general quantity development of about 15 p.c in FY27. Moreover, increased crude oil costs are seen as a optimistic set off for ATBS demand, supporting medium-term stability within the enterprise outlook.
Phase-wise Income Contribution
The corporate’s income is pretty diversified throughout segments, with ATBS contributing round 35 p.c of complete income, making it the most important section. Butyl phenol accounts for about 15 p.c, whereas antioxidants contribute almost 10 p.c of the general combine.
The place IBB types round 11 p.c of income, and IB together with HPMTBE (IB derivatives) contributes shut to fifteen p.c. The remaining 15 p.c comes from different merchandise, together with custom-made chemical substances and components, supporting general portfolio diversification.
The income base is pretty diversified, however ATBS stays the most important single contributor at round one-third of complete gross sales. Together with butyl phenol and antioxidants, the highest specialty chemical segments type the core development engine of the enterprise. The remaining income comes from IB derivatives, IBB, and different custom-made chemical merchandise, which give extra stability and product combine diversification.
How did the ATBS section carry out in This autumn?
The ATBS section delivered robust efficiency through the interval, recording 30 p.c development in FY25, pushed primarily by increased volumes. Demand circumstances remained wholesome, supported by regular industrial consumption, whereas operational enhancements additional strengthened output. The administration highlighted that development was largely volume-led, indicating sturdy underlying demand tendencies within the section.
The corporate additionally maintained a robust management place in ATBS with a worldwide market share of 60 to 65 p.c. Trying forward, demand is anticipated to stay robust with continued double-digit development anticipated in FY26. This displays sustained momentum within the core enterprise, supported by capability readiness and steady end-market demand circumstances.
Capex on the section
The corporate has accomplished its ATBS capability growth, which is scheduled to be absolutely operational by June 2025. This growth is geared toward strengthening manufacturing functionality and assembly rising demand within the ATBS section, which is one in every of its key development drivers. The transfer is anticipated to assist increased quantity development going ahead.
General, the corporate has deliberate a complete capex of round Rs 360 crore for FY26, which incorporates investments in capability growth, new product growth, and operational effectivity enhancements. As well as, the R&D pipeline is robust, with 3 to 4 new merchandise underneath growth that would set off the following part of capex relying on profitable trials.
Concerning the Firm
Vinati Organics Restricted (VOL), included in 1989 and primarily based in Mumbai, is a number one Indian producer of specialty chemical substances and natural intermediaries, commanding a 65–70 p.c international market share in its core merchandise, ATBS and IBB. It’s the world’s largest producer of Isobutyl Benzene (IBB) and 2-Acrylamido-2-methylpropane sulfonic acid (ATBS), serving industries resembling prescribed drugs, water remedy, and private care throughout 35+ nations.
The corporate’s product portfolio contains IBB chemical, which is used within the manufacturing of ibuprofen-based ache aid medicines, and ATBS chemical, which finds software in oil drilling, water remedy, detergents, and different industrial chemical substances.
It additionally produces aroma chemical substances utilized in perfumes, cosmetics, and fragrances, together with specialty components which can be utilized in paints, adhesives, and polymer-based purposes throughout industries.
Monetary Spotlight: The income from operations decreased by 6 p.c to Rs 611 crore in This autumn FY26 (Mar 2026) from Rs 648 crore in This autumn FY25 (Mar 2025), and EBIDT remained flat at Rs 183 crore in This autumn FY26 in comparison with Rs 184 crore in This autumn FY25. Accompanied by a internet revenue development of 8 p.c to Rs 138 crore in This autumn FY26 from Rs 128 crore in This autumn FY25, leading to an EPS development of 8 p.c to Rs 13.26 per share in This autumn FY26.
Disclaimer: The views and funding ideas expressed by funding specialists/broking homes/score businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of economic losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the writer are usually not chargeable for any losses induced on account of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
